Novacyt S.A. (NVYTF)
OTC PINK OTC PINK Primary Summary
NVYTF Chart
Novacyt S.A. (NVYTF) Q4 2024 Earnings Call Transcript
Novacyt S.A. (OTCPK:NVYTF) Q4 2024 Results Conference Call April 30, 2025 6:00 AM ET Company Participants Lyn Rees - Chief Executive Officer Steve Gibson - Chief Financial Officer Operator Good morning, and welcome to the Novacyt Full Year Results Investor Presentation.
Novacyt S.A. (NVYTF) Q2 2024 Earnings Call Transcript
Novacyt S.A. (OTCPK:NVYTF) Q2 2024 Earnings Conference Call September 26, 2024 6:00 AM ET Company Participants Lyn Rees - Chief Executive Officer Steve Gibson - Chief Financial Officer Conference Call Participants Good morning and welcome to the Novacyt Investor presentation.
Novacyt shares drop 16% on legal settlement news
Novacyt SA's (AIM:NCYT, OTC:NVYTF, EPA:ALNOV) share price fell 16% following the announcement of a commercial settlement in its High Court case. The molecular diagnostics company agreed to pay £5 million to the Department of Health and Social Care, resolving all claims and counterclaims.
Novacyt S.A. Dividends
Novacyt S.A. Earnings
| 25 Oct 2024 Date | | - Cons. EPS | - EPS |
| 26 Sep 2024 Date | | - Cons. EPS | - EPS |
| 24 Sep 2024 Date | | - Cons. EPS | - EPS |
| 29 Aug 2024 Date | | - Cons. EPS | - EPS |
| 26 Jun 2024 Date | | - Cons. EPS | - EPS |
| 25 Oct 2024 Date | | - Cons. EPS | - EPS |
| 26 Sep 2024 Date | | - Cons. EPS | - EPS |
| 24 Sep 2024 Date | | - Cons. EPS | - EPS |
| 29 Aug 2024 Date | | - Cons. EPS | - EPS |
| 26 Jun 2024 Date | | - Cons. EPS | - EPS |
Novacyt S.A. (NVYTF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Novacyt S.A. ever had a stock split?
Novacyt S.A. Profile
| Medical Devices Industry | Healthcare Sector | Mr. James Martin McCarthy CEO | OTC PINK Exchange | - ISIN |
| US Country | 120 Employees | - Last Dividend | 28 Jun 2012 Last Split | - IPO Date |
Overview
Novacyt S.A. is a distinguished entity in the global health sector, primarily specializing in the provision of in vitro and molecular diagnostic tests. Since its inception in 2006, the company has been pivotal in addressing a range of infectious diseases. With its headquarters located in Vélizy-Villacoublay, France, Novacyt has broadened its reach, catering to diverse markets including the United Kingdom, other parts of Europe, the United States, Asia Pacific, the Middle East, and Africa. The company’s operation is structured across three main segments: Primer Design, Lab21 Products, and IT-IS International. Each of these segments plays a unique role in Novacyt’s commitment to advancing medical diagnostics, contributing to its reputation as a leader in infectious disease testing.
Products and Services
- Primer Design
This segment of Novacyt S.A. is dedicated to the design, manufacture, and marketing of molecular real-time qPCR testing devices and reagents. Primarily focusing on infectious diseases, products from this division are pivotal in the rapid and accurate detection of pathogens, thereby enabling timely and effective clinical interventions.
- Lab21 Products
Under the Lab21 Products segment, Novacyt expands its diagnostic reach to protein-based infectious disease in-vitro diagnostic device (IVD) products. This line of products is developed, manufactured, and distributed by the company, showcasing its versatility in the production of diagnostic solutions by utilizing different technological bases and methodologies for disease detection.
- IT-IS International
The IT-IS International segment stands out for its specialized focus on the development and manufacturing of PCR (Polymerase Chain Reaction) devices. These devices find their application not only in the life sciences arena but also in the food testing industry, illustrating the broad applicability of Novacyt's technological innovations beyond traditional medical diagnostics.
Contact Information
